Kohji Takemura, MD· @KohjiToncol · X·· 2 天前评分70
正文 · 原文
KEYNOTE-866: Negative for EFS.
ENERGIZE: Negative for EFS.
→ What made the difference between these trials and NIAGARA?
#ESMO26
98 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：Kohji Takemura, MD · x.com